Video

Dr. Stadler on the Utility of Germline Profiling for Targeted Interventions in Advanced Cancer

Zsofia K. Stadler, MD, discusses a study evaluating the clinical utility of germline mutation profiling of targeted therapeutic interventions in a pan-cancer patient population.

Zsofia K. Stadler, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses a study evaluating the clinical utility of germline mutation profiling of targeted therapeutic interventions in a pan-cancer patient population.

Tumor mutational profiling for acquired somatic mutations is paramount for the identification of genetic alterations that have implications for targeted treatment. Results from prior research have established that approximately 10% of patients with advanced cancer harbor somatic mutations that can be targeted with a therapeutic intervention, Stadler explains.

However, much less is known about the clinical utility of germline mutations in patients with advanced cancer. The identification of these alterations is important, as that knowledge can inform risk-reducing measures. For example, a patient with breast cancer whose tumor harbors a BRCA mutation may benefit from a risk-reducing oophorectomy. The detection of germline alterations is also important with regard to cascade testing, says Stadler. Much less is known about how these alterations can be used to select for targeted therapeutic interventions—especially in the advanced cancer setting.

To this end, Stadler and colleagues aimed to assess the clinical utility of germline mutation profiling in known cancer susceptibility genes for targeted therapeutic interventions in a pan-cancer patient population, Stadler concludes. Results from the research were presented at the 2020 ASCO Virtual Scientific Program.

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing [email protected], or by calling 833-315-2722.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity